$IVOB Management Heading to Argentina and Egypt Next Week
October 26th, 2009 at 8:28 am Posted by
Next week, $IVOB management will be attending two separate infertility conferences that could have $IVOB seeing more gains.
Early in the week, $IVOB President and Chief Scientific Officer Dr. Claude Ranoux will be be attending the Procrearte Infertility Network Meeting in Bueno Aires, Argentina. $IVOB has already established various connections in the infertility industry through 3 distribution contracts for 15 countries including Columbia, Venezuela, Ecuador, Panama, Mexico, Brazil, Chile, Argentina and Uruguay.
In addition, $IVOB‘s ties with the Nacer and CER Centers for Human Reproduction gives them access to Peru, Guatemala, Belize, El Salvador and Honduras.
The Dean believes that this much market penetration so far gives $IVOB‘s INVO procedure and INVOcell device credibility that could serve favorable in Argentina next week. There, Dr. Ranoux will be speaking to more than 150 reproductive health specialists and giving training workshops to the Procrearte group which has many fertility centers in Peru, Uruguay, Columbia, Argentina and other South American countries.
$IVOB already has a distribution agreement with The Daxley Group in this area and could easily expand the $IVOB IVF empire in the Latin and South American regions.
The Dean’s particularly excited about $IVOB because at virtually the same time next week $IVOB CEO Kathleen Karloff will be attending the 16th Annual Meeting of the Middle East Fertility Society in Cairo, Egypt where $IVOB‘s distribution arm in the Middle East, Galaxy IVF, will be presenting the data of a clinical study of the first 100 commercial cycles of the INVO procedure performed in the region.
The Dean believes that big news could be contained in these results and could bring further distribution and use of the INVOcell device in multiple countries in the Middle East.
$IVOB is all over Galaxy IVF’s website where the INVOcell device is described as “a new fertility treatment that can be performed successfully in the office on an infertility specialist.” The INVO procedure is also referred to as “less expensive and easier to perform than conventional in vitro fertilization.”
The Dean believes this is a sign of progress and credibility and, as $IVOB CEO Kathleen Karloff has suggested, “Presenting this data validates INVO as an effective treatment for infertility in this region” and “This validation will allow INVO and Galaxy to extend sales throughout the Middle East.”
Ultimately, The Dean believes next week’s conferences are another positive step for $IVOB and could be a sign of more things to come.
congratulations Dean – impressive new volume monday-tuesday should help keep IVOB away from 40¢ trading at least through the November reveals.